NCT05349474View on ClinicalTrials.gov

Metformin Treatment in Progressive Multiple Sclerosis

EARLY_PHASE1CompletedINTERVENTIONAL
Enrollment

23

Participants

Timeline

Start Date

April 26, 2022

Primary Completion Date

May 30, 2025

Study Completion Date

May 30, 2025

Conditions
Secondary Progressive Multiple SclerosisPrimary Progressive Multiple Sclerosis
Interventions
DRUG

Metformin 500 Mg Oral Tablet, up to 4 tablets a day

Metformin 500 mg oral tablets to be titrated to 2000 mg/day divided over two doses or maximum tolerated dose

DRUG

Placebo oral tablet identical to metformin, up to 4 tablets a day

Placebo tablets identical to metformin tablets. To be titrated to four tablets divded over two doses or maximum tolerated dose

Trial Locations (1)

90095

University of California, Los Angeles, Los Angeles

All Listed Sponsors
lead

University of California, Los Angeles

OTHER